Canopy Growth Corp
TSX:WEED
Canopy Growth Corp
TSX:WEED
Price:
13.28 CAD
3.51%
Updated:
May 15, 2024
Section:
Relative Value
The Relative Value of one
WEED
stock under the Base Case scenario is
10.45
CAD.
Compared to the current market price of 13.28 CAD,
Canopy Growth Corp
is
Overvalued by 21%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
WEED
Relative Value
Base Case
10.45
CAD
Overvaluation 21%
Valuation Multiples
Multiples Across Competitors
WEED Competitors Multiples
Canopy Growth Corp Competitors
Canopy Growth Corp Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| CA |
|
Canopy Growth Corp
TSX:WEED
|
1.1B CAD | 3.7 | -0.9 | -5.5 | -4.5 | |
| JP |
N
|
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
|
776 550.9T JPY | 4 211 733 | -5 347 888.9 | -5 459 134.4 | -5 046 864.6 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
737.3B USD | 20.6 | 120.4 | 58.8 | 66.9 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
4.1T DKK | 16.7 | 45.8 | 34.1 | 37.5 | |
| UK |
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP | 578.3 | -15 783.5 | 3 846.3 | 17 702.3 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
364.3B USD | 4.3 | 9.5 | 11.7 | 15.2 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
329.3B USD | 5.4 | 143.1 | 35.6 | 58.1 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
189.6B GBP | 5 | 37.7 | 174.5 | 278.4 | |
| CH |
|
Novartis AG
SIX:NOVN
|
182.6B CHF | 3.4 | 11.5 | 8.7 | 12.8 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
181.5B CHF | 3.1 | 15.8 | 9 | 10.6 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
161.6B USD | 2.9 | -524 | 12.9 | 20.6 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
You don't have any saved screeners yet
